Double-blind, randomized, placebo-controlled, prospective Phase III study evaluating efficacy and safety of Panzyga in Primary Infection Prophylaxis in patients with Chronic Lymphocytic Leukemia (PRO-SID study)
Study of Panzyga in Primary Infection Prophylaxis (Prevention) in Patients with Chronic Lymphocytic Leukemia (PRO-SID)
Sponsor: Octapharma
Enrolling: Male and Female Patients
IRB Number: AAAS9002
U.S. Govt. ID: NCT04502030
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: This study will be performed to determine if Panzyga (the study drug) can help with preventing infections in patients who have chronic lymphocytic leukemia (CLL). Panzyga is a study drug administered via injection into the vein, which contains human antibodies also called immunoglobulins. It is manufactured by Octapharma. Your participation in this clinical study will last for about 55 weeks. The study will be conducted at approximately 50 study centers worldwide. In total, at least 256 adult patients will take part in this study.
Nicole Lamanna, MD
Do You Qualify?
Are 18 years of age or older? Yes No
Do you have diagnosis of Chronic Lymphocytic Leukemia (CLL)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator